Modified form of the analytical solution (Eq (23)) of ICFFL motif. by Alok Kumar Maity (2212204)

Modified forms of the analytical solution (Eq 18) of ACFFL motif. by Alok Kumar Maity (2212204)

<b>Anti-inflammation</b><b> </b><b>of </b><b>Rhapontici Radix</b><b> </b><b>mediated by </b><b>TMEM59 in MAC-T cells and mouse mammary gland</b> by Caode Jiang (11273817)

Modified form of the analytical expression given by Eq (11) for OSC motif. by Alok Kumar Maity (2212204)

Schematic presentation of different GTRN motifs. by Alok Kumar Maity (2212204)

Comparison of RMSE scores for the imputation of 269 highly differentially expressed genes of the A549 cell line. by Tong Si (1600378)

Results of the probabilistic sensitivity analysis. by Lara J. Wolfson (7224623)

Simultaneous HuD knockdown and overexpression of Msi2 reduces apoptosis in N2a cells. by Naina Gaikwad (20435889)

The OSC. by Alok Kumar Maity (2212204)

The ACFFL. by Alok Kumar Maity (2212204)

The TSC. by Alok Kumar Maity (2212204)

The OCFFL. by Alok Kumar Maity (2212204)

The ICFFL. by Alok Kumar Maity (2212204)

CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts by Janak L. Pathak (759122)

Modeling of <i>In-Utero</i> and <i>Intra-Partum</i> Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV by Patumrat Sripan (741310)

“…We modeled <i>in-utero</i> and <i>intra-partum</i> HIV transmissions to investigate the preventive role of various antiretroviral treatments interventions.…”

Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Tao Cheng (1235148)

“…The onabotulinumtoxinA-treated groups had a significantly decreased mean number of urinary incontinence episodes per week (at week 6) (onabotulinumtoxinA200U: MD: -10.72, 95% CI: -13.4 to -8.04, P<0.00001; 300 U: MD: -11.42, 95% CI: -13.91 to -8.93, P<0.00001), MDP (200 U: MD: -33.46, 95% CI: -39.74 to -27.18, P<0.00001; 300 U: MD: -31.72, 95% CI: -37.69 to -25.75, P<0.00001), and greater increased MCC (200 U: MD: 141.30, 95% CI: 121.28 to 161.32, P<0.00001; 300 U: MD: 151.39, 95% CI: 130.43 to 172.34, P<0.00001) compared to the placebo-treated groups. …”

The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors by T. Ghiasi (10910038)

“…<p>Robust and reliable QSAR models were developed to predict half-maximal inhibitory concentration (IC₅₀) values of hepatitis C virus NS3/4A protease inhibitors from the Monte Carlo technique. 524 HCV NS3/4A protease inhibitors were extracted from the scientific literature to create a reasonably large set. …”

Heart specific RNase Z variants show a mild decrease in longevity and locomotor response. by Ekaterina Migunova (15909887)

Effects of magnesium supplementation on growth of the Δ<i>corA</i>Δ<i>mgtA</i> mutants and their ability to compete with the wild-type strain. by Selma Metaane (12329248)

Difference from baseline to 24 weeks for increasing and decreasing VW-MTR in T2-LV in patients. by Robert Zivadinov (105393)